Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT and FLT3 in hematologic malignancies: Mutant KIT and FLT3 response to Tyrosine Kinase Inhibitors

Mutations in two type-3 receptor tyrosine kinases (RTK), KIT and FLT3, are common in both acute myeloid leukemia (AML) and systemic mastocytosis (SM) and lead to hyperactivation of key signaling pathways. Fortunately, a significant number of tyrosine kinase inhibitors TKIs have been developed that t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Br J Haematol
Hauptverfasser: Weisberg, Ellen, Meng, Chengcheng, Case, Abigail, Sattler, Martin, Tiv, Hong L., Gokhale, Prafulla C., Buhrlage, Sara, Liu, Xiaoxi, Yang, Jing, Wang, Jinhua, Gray, Nathanael, Stone, Richard, Adamia, Sophia, Dubreuil, Patrice, Letard, Sebastien, Griffin, James D.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2019
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7887860/
https://ncbi.nlm.nih.gov/pubmed/31309543
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16092
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge